Drug intelligence / Profile preview

AVA2206

Development stage: Unknown
Lead developer: Averoa
Modality: Small Molecules

Overview

AVA2206 is a small molecule antioxidant being developed by Averoa Pharma for the treatment and prevention of rare forms of renal lithiasis (kidney stones), such as cystine lithiasis. Developed as part of the LUCIOL project, the compound is designed to address rare metabolic kidney diseases through its antioxidative properties. It is intended to be used in conjunction with a companion diagnostic, AVA2065, to identify and monitor patients. As of early 2026, the drug is in late preclinical stages and preparing for Phase I clinical evaluation.

Beyond the preview

Go deeper on AVA2206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVA2206.

Explore the full profile